KalVista Pharmaceuticals Earnings Call Summary Company Overview - **Company**: KalVista Pharmaceuticals (NasdaqGM: KALV) - **Event**: Earnings call for the 8-month fiscal year 2025 financial results and corporate update - **Date**: March 25, 2026 Key Points Industry and Product Launch - **Product**: EKTERLY, the first and only oral on-demand treatment for hereditary angioedema (HAE) [4][5] - **Launch Details**: - Launched in the U.S. on July 7, 2025, with strong early adoption and positive feedback from patients and physicians [4][5] - Global expansion includes launches in Germany and Japan, with a partnership in Latin America for sebetralstat [6] Financial Performance - **Revenue**: - Global net product revenue for the fourth quarter was $35 million, totaling $49 million from launch through December 31, 2025 [5][21] - **Operating Expenses**: - Total operating expenses were $160.2 million, up from $117 million in the prior year [21][22] - Research and development expenses decreased to $33.4 million from $52.2 million due to lower clinical trial costs [22] - SG&A expenses increased to $124.7 million, driven by commercial launch activities [22] Market Engagement and Adoption - **Patient Engagement**: - 1,702 patient start forms received, with 724 unique prescribers activated in the U.S. [5][15] - Refills now represent the majority of prescriptions, indicating sustained usage and confidence in EKTERLY [5][18] - **Market Penetration**: - Approximately 20% of the estimated 9,000 U.S. HAE patients have initiated EKTERLY [16][18] - Strong engagement from top prescribers, with 29 of the top 30 HAE prescribers prescribing EKTERLY [17] Clinical Evidence and Recommendations - **Clinical Data**: - Presented new analyses at AAAAI and Western Allergy meetings showing high patient satisfaction (91.1% rated neutral to extremely satisfied) and effective treatment patterns [11][12] - EKTERLY recommended as a first-line treatment for adolescents aged 12 and older in the International Guideline on HAE management [8][13] - **Pediatric Opportunity**: - Plans to submit an NDA for pediatric use in children ages 2 to 11 in Q3 2026, with potential U.S. launch in 2027 [7] Future Outlook - **Growth Strategy**: - Focus on expanding access globally and enhancing clinical evidence to support long-term growth [9][26] - Anticipated operating expenses to remain consistent, with an increase in cost of revenue as inventory is sold [25] - **Market Dynamics**: - Expectation that the U.S. will represent approximately 85% of peak sales, with the remainder from ex-U.S. markets [30] - Transition to oral therapies expected to increase treatment rates and overall market size [66][67] Reimbursement and Access - **Payer Access**: - Ongoing efforts to convert patients across all payers, leveraging medical exceptions and active policies [75] - Anticipation of steady state access realization later in 2026 [75] Short-Term Prophylaxis (STP) Opportunity - **Research Initiatives**: - Ongoing studies to evaluate EKTERLY's use in short-term prophylaxis, with promising preliminary data [76][78] Additional Insights - **Patient Experience**: - High ratings for patient support services, indicating strong satisfaction beyond the product itself [19] - **Market Trends**: - Observations of refill patterns suggest high-burden patients refill more frequently than those with mild to moderate disease [60][61] This summary encapsulates the key points from the earnings call, highlighting the company's performance, product launch, market engagement, clinical evidence, and future strategies.

Core Insights - BioCryst Pharmaceuticals received FDA approval for ORLADEYO oral pellets for children aged 2 to less than 12 in December 2025, addressing a significant unmet need in hereditary angioedema (HAE) treatment [1] - The company reported strong financial performance for 2025, with ORLADEYO revenue reaching $601.8 million, a 38% increase year-over-year, and expects continued growth in 2026 [3][4] - BioCryst is advancing its pipeline, including navenibart, which is in pivotal Phase 3 trials, and BCX17725 for Netherton syndrome, with promising early results [6][10] Financial Performance - ORLADEYO revenue for 2025 was $601.8 million, up 38% year-over-year, and 43% when excluding the European business sold in October [3][4] - Non-GAAP operating profit rose to $214 million, a 198% increase year-over-year, marking the highest in company history [13] - The company ended 2025 with $337.5 million in cash and investments and entered a $400 million financing facility with Blackstone Life Sciences [14] Product Development and Pipeline - Navenibart is currently enrolling in the Phase 3 Alpha Orbit trial, targeting approximately 145 patients by mid-2026, with a BLA submission expected after mid-2027 [4][6] - Phase 2 data for navenibart showed significant attack-rate reductions, with mean reductions of 90-92% [7] - The company is also advancing BCX17725 for Netherton syndrome, with completed Phase 1 trials showing safety and tolerability [10][11] Market Positioning and Strategy - BioCryst views the HAE market as "structurally segmented," emphasizing that treatment choices are driven by patient needs rather than a single efficacy leader [3] - The pediatric launch of ORLADEYO is included in 2026 guidance but is expected to be a small contributor in the near term [5] - The company implemented a 9% price increase for ORLADEYO in January, expecting to net about half of that increase [15]

Summary of Pharvaris FY Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Treatment of Hereditary Angioedema (HAE), a rare genetic condition characterized by painful and potentially fatal swelling attacks [4][5] Core Points and Arguments Company Background - Pharvaris was established 10 years ago, with a focus on addressing unmet needs in HAE treatment, particularly for an oral therapy option [4][6] - The company aims to develop deucrictibant, an oral B2 receptor antagonist, to provide a highly efficacious treatment for HAE and other forms of angioedema [7][8] Market Dynamics - The current market for HAE treatments is dominated by injectables, with approximately 63% of patients on long-term prophylaxis, representing about 80% of the market value [12][13] - The clinical guidelines suggest that ideally, HAE patients should never suffer from attacks, highlighting the need for effective prophylactic treatments [13] Clinical Data - The Phase 3 trial for deucrictibant in the on-demand setting showed significant results, with a primary endpoint met and all 11 secondary endpoints achieving statistical significance [16] - Key findings include: - Onset of symptom relief at 1.28 hours compared to 12 hours for placebo [17] - End of progression of the attack at 17 minutes, providing comfort to patients [17] - Faster complete resolution compared to standard care and recently approved oral therapies [19] Competitive Landscape - The oral therapy market is becoming increasingly competitive, with KalVista's EKTERLY recently launched. However, deucrictibant is positioned to differentiate itself through faster onset and resolution of symptoms [21][22] - The Phase 2 data for deucrictibant in the prophylactic setting showed an 84.5% attack reduction, comparable to injectable therapies [41] Regulatory and Commercial Strategy - Pharvaris plans to file for NDA in the first half of 2026, with a potential launch about a year later [20] - The company is expanding its Phase 3 studies to include a broader patient demographic and geographic range, which may mitigate risks associated with trial outcomes [45] Financial Outlook - The company has sufficient cash runway into the first half of 2027, with plans to ramp up commercial operations and team expansion [56][57] Additional Important Information - Pharvaris will present at the QUAD A conference, showcasing Phase 3 data and other significant findings, including a 92.3% attack reduction from an open-label extension study [53] - The company is also involved in community engagement, sponsoring events like the HAEA Foundation's 5K run [54] This summary encapsulates the key points discussed during the Pharvaris FY conference call, highlighting the company's strategic focus, clinical advancements, market positioning, and financial outlook.

Core Insights - BioCryst Pharmaceuticals has completed the acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE) and supporting long-term growth [1][5] Acquisition Details - The acquisition was valued at approximately $700 million, financed through cash on hand and a financing facility, with BioCryst issuing about 37.3 million shares to Astria's equity holders [5] Product Portfolio Enhancement - BioCryst adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development, which could be the first HAE therapy with every-three and every-six month dosing, improving patient treatment experiences [2][3] - The company now offers both the leading oral therapy (ORLADEYO®) and a potentially best-in-class injectable option, providing optimal choices for individualized patient care [3] Strategic Leadership Changes - Jill C. Milne, Ph.D., co-founder and CEO of Astria, has joined BioCryst's Board of Directors, while John Ruesch has been appointed as Chief Technical Operations Officer, bringing expertise in product development [6] Additional Programs - BioCryst has acquired Astria's early-stage program for atopic dermatitis, STAR0310, and plans to explore strategic alternatives for this program [4]

Core Insights - BioCryst Pharmaceuticals has received FDA approval for ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for pediatric patients with hereditary angioedema (HAE) aged 2 to less than 12 years [1][4][12] Group 1: Product Details - ORLADEYO is now available in an oral pellet formulation, designed for easier administration to children, allowing it to be swallowed directly or sprinkled over soft food [6][9] - The approval was based on positive interim data from the APeX-P clinical trial, which demonstrated that ORLADEYO was well tolerated and resulted in early and sustained reductions in monthly attack rates for pediatric patients [5][7] Group 2: Market Context - Approximately 40% of children with HAE experience their first attack by age 5, highlighting the need for effective treatment options that are less burdensome than intravenous or subcutaneous therapies [2] - The introduction of ORLADEYO oral pellets is expected to change the management of HAE in younger patients, providing a more convenient option for families and caregivers [9] Group 3: Company Commitment - BioCryst is committed to supporting patients through its Empower Patient Services, which offers comprehensive assistance for navigating insurance and treatment needs [10] - The company has plans for additional regulatory filings for ORLADEYO in other regions, including Europe and Japan, indicating a strategy for global market expansion [8]

Core Insights - Saturn V Capital Management has initiated a new position in Pharvaris N.V. (PHVS), acquiring 886,332 shares valued at approximately $22.1 million during the third quarter, indicating strong interest from a major hedge fund in the biotech sector [1][2]. Company Overview - Pharvaris N.V. is a clinical-stage biotechnology company focused on developing novel oral therapies for hereditary angioedema (HAE), a rare genetic disorder [6][9]. - The company has three pivotal programs underway: PHA121 (Phase II), PHVS416 (Phase II), and PHVS719 (Phase I), targeting both acute and prophylactic treatment needs [9][10]. - As of market close on the reporting date, Pharvaris shares were priced at $25.35, reflecting a 33% increase over the past year, outperforming the S&P 500, which rose by 12% in the same period [3][4]. Financial Metrics - Pharvaris has a market capitalization of $1.6 billion and reported a net income of -$163.7 million for the trailing twelve months (TTM) [4]. - The company had €329 million in cash on hand as of September 30, which is expected to finance operations into the first half of 2027, covering major data readouts [10]. Investment Implications - Saturn V's stake in Pharvaris represents about 4.9% of its 13F assets, aligning with the fund's focus on biotech investments and high-conviction clinical risks [3][11]. - Recent positive topline data from the RAPIDe-3 Phase 3 trial showed a median time to onset of symptom relief of 1.3 hours, highlighting the potential for future growth despite the company being pre-revenue [11][12].

Core Insights - Pharvaris (PHVS) shares increased nearly 22% following positive results from the phase III RAPIDe-3 study for its drug deucrictibant, aimed at treating hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older [2][8] Study Results - The RAPIDe-3 study achieved its primary endpoint, with patients experiencing symptom relief within 1.28 hours after taking deucrictibant, compared to over 12 hours with placebo [3] - All secondary endpoints were met, including a median time to substantial symptom relief of under 3 hours with deucrictibant versus over 12 hours with placebo, and complete symptom resolution in 11.95 hours compared to more than 24 hours for placebo [3] - 83% of HAE attacks were managed with a single dose of deucrictibant, and over 93% of attacks were treated without the need for backup treatment [4] Regulatory Plans - Pharvaris plans to submit a regulatory filing for deucrictibant in the first half of 2026, which could position it as the second oral on-demand therapy for HAE after KalVista Pharmaceuticals' Ekterly [5] Competitive Landscape - Comparisons between deucrictibant and KalVista's Ekterly highlight potential advantages for deucrictibant, as it showed faster symptom relief in the RAPIDe-3 study compared to the KONFIDENT study supporting Ekterly's approval [6] - Year-to-date, Pharvaris stock has risen 53%, outperforming the industry growth of 20% [7] Product Development - Pharvaris is developing two formulations of deucrictibant: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic treatment [10] - The extended-release tablet is being evaluated in the phase III CHAPTER-3 study for HAE prophylaxis, with top-line data expected in the second half of 2026 [11] - Additionally, the extended-release formulation is under evaluation in the CREAATE study for treating acquired angioedema with C1-inhibitor deficiency [12] Market Positioning - If approved, deucrictibant will compete in the on-demand treatment space against KalVista's Ekterly, with advantages over older injectable treatments like Firazyr and Kalbitor due to its oral administration [14] - In the prophylactic treatment segment, competitors include BioCryst Pharmaceuticals and Ionis Pharmaceuticals, with BioCryst's Orladeyo and Ionis' Dawnzera being notable products [15]

Core Insights - Pharvaris N.V. is focused on developing treatments for rare diseases, particularly Hereditary Angioedema (HAE) [1][6] - Morgan Stanley has an "Overweight" rating for Pharvaris, raising the price target from $37 to $41, with the current stock price at $29.37 [1][6] Study Results - The RAPIDe-3 Phase III study of Deucrictibant showed a median time to symptom relief of 1.28 hours, significantly faster than placebo [2][3][6] - The study involved 134 participants aged 12 and older, demonstrating the efficacy of Deucrictibant in treating HAE attacks [2] - 83% of attacks were treated with a single capsule, and 93.2% of participants did not require rescue medication within 12 hours [3] Future Plans - Pharvaris plans to use the RAPIDe-3 study data for marketing authorization applications, expected to be submitted in the first half of 2026 [3][6] - The positive results from the study have contributed to an increase in PHVS stock value by 21.75% [6] Market Performance - Pharvaris' current stock price is $29.37, reflecting a change of $5.25, with a market capitalization of approximately $1.91 billion [5][6] - The stock has fluctuated between $23.80 and $29.68 today, with a 52-week high of $29.67 and a low of $11.51 [5]

Core Insights - Pharvaris N.V. announced topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for treating hereditary angioedema (HAE) attacks, indicating positive results for the on-demand treatment [1][3] Study Results - The RAPIDe-3 trial enrolled 134 participants aged 12 years and older, evaluating the oral deucrictibant immediate-release (IR) capsule for HAE attacks [2] - Deucrictibant showed a faster median time to treatment response compared to placebo, with shorter median times for substantial symptom relief and complete symptom resolution [3] - The data indicated fewer attacks required a second dose or rescue medication within 12 hours [4] - 83.0% of attacks were treated with a single capsule of deucrictibant IR, and 93.2% of treated attacks did not require rescue medication [9] Safety and Tolerability - Deucrictibant was well tolerated, with no serious treatment-related adverse events reported, and no participants discontinued treatment due to adverse events [5] Future Plans - The data from the RAPIDe-3 study will support marketing authorization applications planned for submission in the first half of 2026 [3] Competitive Landscape - The FDA approved Ionis Pharmaceuticals' Dawnzera for HAE prophylaxis, which significantly reduced the monthly attack rate by 81% compared to placebo over 24 weeks [6] - KalVista Pharmaceuticals' Ekterly was also approved for acute HAE attacks, being the first oral on-demand treatment for HAE [7] Market Reaction - Pharvaris shares increased by 12.32% to $27.09 following the announcement of the trial results [7]

Core Insights - KalVista Pharmaceuticals reported strong momentum in the US launch of EKTERLY®, achieving $13.7 million in net product revenue for the third quarter of 2025, with 937 patient start forms received by October 31, 2025 [1][3][9] - The company has successfully launched EKTERLY in Germany, with initial orders indicating positive demand, and has received regulatory approval in Australia, expanding its global footprint [2][3] - As of September 30, 2025, KalVista has approximately $309 million in cash, expected to fund operations until profitability [1][9] Commercial Progress - The US commercial launch of EKTERLY began on July 7, 2025, with 423 unique prescribers activated [3] - EKTERLY is the first and only oral on-demand treatment for hereditary angioedema (HAE) approved in the US, EU, Switzerland, and Australia [6][9] - The European Commission and Swissmedic approved EKTERLY for treating acute HAE attacks in adults and adolescents aged 12 and older [3] Financial Performance - For the three months ended September 30, 2025, KalVista reported a net product revenue of $13.7 million, with a cost of revenue of $1.2 million [9][12] - Research and development expenses decreased to $12 million from $18.7 million in the same period of 2024, primarily due to reduced clinical trial costs [9][12] - Selling, general and administrative expenses increased to $46.5 million from $24.8 million, attributed to commercialization efforts for EKTERLY [9][12] Organizational Updates - The company appointed Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer [9] - Bethany L. Sensenig joined KalVista's Board of Directors and the Audit Committee [9] Clinical Highlights - Interim results from the KONFIDENT-KID trial showed a median time to dosing of 30 minutes and a median time to symptom relief of 1.5 hours for pediatric patients [9] - In the KONFIDENT-S trial, 84% of treated attacks were rated as satisfied by patients who switched from injectable treatments [9]